Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
I asked this question on Telegram too. I think the questions are probably too big for a single answer so I am hoping for a discussion. I am trying to figure the rationale and thinking behind targeting cancer from different points of view; Angle - Parsortix, a CSO of an immunotherapy company or drug development company, medtech company and last by no means least a clinician/oncologist.
So firstly, the rationale and thinking of the individual, say Andrew Newland, Ugur Sahin (BionTech). Then the mantra and culture of the organisation; maybe an expanded view of the top scientist? Importantly what is the approach.
I ask this because it seems to me that all have a different approach, yet in theory they should meet in the middle. Maybe at this point collaboration can be made. I don't see there being an exact middle by the way, maybe more of an overlap.
Let me give you an example without getting too tied up in the science (because I don't have a deep understanding of it). For instance lets say Sahin of Biontech has an objective in mind to cure cancer with immunotherapy. He really doesn't need Parsortix at the point of conception. His thinking is driven by a arguably a unique understanding and depth of knowledge that is amongst the very best in the world - and - he is taking his own journey as such talented scientist's do. Maybe years of work (10?) even a lifetimes work. He is likely to be appreciative of the changing wider landscape but he has to remain focused.
I would assume that he can see the clinical relevance of Parsortix and how it may fit in with his agenda. However as Angle are running a business, the onus is upon them to accommodate and tailor a message specifically to Sahin (or whoever) or his staff of the clear benefits of Parsortix; its just necessary.
So if I go back to the beginning, where does Parsortix fit in?
I think when it comes to clinicians, they use the tools available to them don't they? These people are doers as well as thinkers but ultimately they make decisions. So the mentality is quite different in many ways to a drug developer.
Yet Angle have to navigate a landscape where they are dealing with the whole of the cancer treatment community. No easy task.
With such investments as Angle, we do the research that is relevant to the investment. That can leave us with a lopsided understanding of the wider science of cancer. I call this the Professor Brian Cox effect - we can all what and understand what he is telling us but only he truly owns the knowledge. We are just borrowing his words and phrases. Try telling someone what he said and what it means and you soon find how limited your understanding is!
Anyway - thoughts
Excellent information TT. Thanks for joining up the dots. A fair few of us are already in the area with another company and can confirm infrastructure and assets are there.
Good Luck
Ruck,
I don't disagree that significant or relevant news should be communicated to the market in good time (Nomad approvals etc), but it is surprising how often data/news appears so very close to an AGM. For instance another excellent company I am invested in has announced best in class ovarian cancer results just days before the AGM. This news was very significantly delayed - maybe as long as 10 months. I am not saying that Companies wait for an AGM to announce but if an AGM is reasonably close it would certainly help to announce good news the week before. Also the company is allowed to take time to interpret the information it seems? Not sure if there is a discretionary period.
Not really. I am in GGP, ANGLE PLC and Scancell. All of whom have had outstanding updates over the last month or so. It is a fact that private investors are not buying as they recognise the market is declining. Institutions have to consider should they hold or sell. Lack of buying is the problem and that is due to economic and geopolitical circumstances.
I am very happy to be in all three as they continue to deliver outstanding news
Flatlander,
Good to see you are taking such an analytical approach. Just be careful you do not corrupt your own view by focusing on unnecessary tangents. It is just as good (although different) to zoom out as well as in. Doing both is my ideal. Sometimes one has to just go with it. Especially when the fundamental value is not reflected in the share price. Given the achievements of the last twelve months and the years of work that proceeded it, the cash at hand, the fact there is no debt and little dilution - this appears to be the proverbial no brainer.
1.
I know some of us have suffered with the stocks we hold recently and with Scancell for a long time but this just underlines good research, conviction and calm temperament can pay off. Nice to see a few more pounds in our long suffering portfolio's.
2.
Redmile, Vulpes and our other stalwart backers must be pleased!
3.
A much bigger congratulations to the Scancell team who after all,l have put in a lot of hard work on all platforms. May there be more great news and rewards to come.
4.
Personally I would like to thank our two favorite posters and their apprentice (you know who you are). All the old timers too that have guided us with some excellent contributions and analysis. For a simpleton like me these have been very helpful and encouraged me to hold.
I think in effect Angle are conducting a consultancy period with ALL its potential customers which is taking time. Now we have regulatory approval the conversation can be serious rather than just interesting. However, it it clear that Angle have to match the customer needs to enable sales. So, it it is relevant assays etc then we should be assured that Angle will be carrying out these works. Sales will follow but its not quite like selling burgers. Our customers don't buy on impulse like McDonalds customers do. It is all about planning and preparation. This will lead to long contracts.